{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T06:17:10Z","timestamp":1792304230376,"version":"4.4.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:p>Blockade of immune checkpoint pathways such as the programmed cell death protein 1 pathway (PD-1\/PD-L1) is an emerging approach in the treatment of solid tumors. In malignant melanoma, the efficiacy of antibodies against PD-L1 has been shown to be associated with PD-L1 protein expression. To evaluate whether this approach may be of use in the rare cases of primary melanoma of the vulva, we have evaluated a series of 13 cases for PD-L1 expression as well as additional molecular alterations of <jats:italic toggle=\"yes\">KIT, NRAS, KRAS<\/jats:italic>, and <jats:italic toggle=\"yes\">BRAF<\/jats:italic>. PD-L1 expression was detected in 69% of cases and was not associated with any other molecular alteration, tumor stage or morphology. In conclusion, targeting PD-L1 by selective antibodies may be of benefit in the treatment of these uncommon tumors.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000454","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T23:32:33Z","timestamp":1505345553000},"page":"477-481","source":"Crossref","is-referenced-by-count":12,"title":["Frequent PD-L1 Expression in Malignant Melanomas of the Vulva"],"prefix":"10.1097","volume":"37","author":[{"given":"Banafsheh","family":"Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Kriegsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Aulmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230824","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1273::AID-CNCR24>3.0.CO;2-Z","article-title":"Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: predictors of survival","volume":"86","author":"Ragnarsson-Olding","year":"1999","journal-title":"Cancer"},{"key":"R2-20230824","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2011.11.921","article-title":"Clinicopathologic study of 85 cases of melanoma of the female genitalia","volume":"67","author":"Tcheung","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R3-20230824","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1158\/1078-0432.CCR-03-0562","article-title":"Exon 15 BRAF mutations are uncommon in melanomas arising in non sun-exposed sites","volume":"10","author":"Cohen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R4-20230824","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol"},{"key":"R5-20230824","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/sj.bjc.6604791","article-title":"Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas","volume":"99","author":"Satzger","year":"2008","journal-title":"Br J Cancer"},{"key":"R6-20230824","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/modpathol.2013.211","article-title":"Comparison of molecular abnormalities in vulvar and vaginal melanomas","volume":"27","author":"Aulmann","year":"2014","journal-title":"Mod Pathol"},{"key":"R7-20230824","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J Clin Oncol"},{"key":"R8-20230824","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1183\/09031936.00105911","article-title":"Clonality of multifocal non-small cell lung cancer: implications for staging and therapy","volume":"39","author":"Warth","year":"2012","journal-title":"Eur Respir J"},{"key":"R9-20230824","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"R10-20230824","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/jcp.2004.021766","article-title":"The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated","volume":"58","author":"Penzel","year":"2005","journal-title":"J Clin Pathol"},{"key":"R11-20230824","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/0002-9378(94)90137-6","article-title":"Malignant melanoma of the vulva and vagina in the United States: patterns of incidence and population-based estimates of survival","volume":"171","author":"Weinstock","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"R12-20230824","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/1097-0142(19930301)71:5<1893::AID-CNCR2820710528>3.0.CO;2-7","article-title":"Malignant melanoma of the vulva and vagina. Trends in incidence, age distribution, and long-term survival among 245 consecutive cases in Sweden 1960\u20131984","volume":"71","author":"Ragnarsson-Olding","year":"1993","journal-title":"Cancer"},{"key":"R13-20230824","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1002\/1097-0142(19940515)73:10<2626::AID-CNCR2820731026>3.0.CO;2-U","article-title":"Malignant melanoma of the vulva treated by radical hemivulvectomy. A prospective study of the Gynecologic Oncology Group","volume":"73","author":"Phillips","year":"1994","journal-title":"Cancer"},{"key":"R14-20230824","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/1097-0142(19950101)75:1<72::AID-CNCR2820750113>3.0.CO;2-G","article-title":"Malignant melanoma of the vulva. Evaluation of prognostic factors with emphasis on DNA ploidy in 75 patients","volume":"75","author":"Scheistroen","year":"1995","journal-title":"Cancer"},{"key":"R15-20230824","first-page":"1017","article-title":"Melanomas of the vulva and vagina","volume":"10","author":"Trimble","year":"1996","journal-title":"Oncology"},{"key":"R16-20230824","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1245\/s10434-014-4215-3","article-title":"Melanoma of the vulva and vagina: principles of staging and their revelevance to managemant based on a clinicopathologic analysis of 85 cases","volume":"22","author":"Seifried","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R17-20230824","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"key":"R18-20230824","first-page":"883","article-title":"Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma","volume":"149","author":"van Elsas","year":"1996","journal-title":"Am J Pathol"},{"key":"R20-20230824","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Ex-pression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int Immunol"},{"key":"R21-20230824","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"R22-20230824","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Associationof pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"R23-20230824","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"R24-20230824","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00004347-201809000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T01:35:33Z","timestamp":1692840933000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004347-201809000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000454","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}